Scholars@Duke publication: Phase I trial of continuously infused gemcitabine with mitoxantrone for high risk or relapsed acute leukemia.

Phase I trial of continuously infused gemcitabine with mitoxantrone for high risk or relapsed acute leukemia.

Publication , Journal Article

Rizzieri, DA; Gockerman, JP; DeCastro, CM; Petros, WP; Lilly, S; Davis, PH; Foster, T; Jarrell, E; Laughlin, MJ; Adams, DJ; Moore, JO

Published in: BLOOD

November 16, 2000

BLOOD

0006-4971

November 16, 2000

326A / 326A

AMER SOC HEMATOLOGY

APA

Chicago

ICMJE

MLA

NLM

Rizzieri, D. A., Gockerman, J. P., DeCastro, C. M., Petros, W. P., Lilly, S., Davis, P. H., … Moore, J. O. (2000). Phase I trial of continuously infused gemcitabine with mitoxantrone for high risk or relapsed acute leukemia. BLOOD, 96(11), 326A-326A.

Rizzieri, D. A., J. P. Gockerman, C. M. DeCastro, W. P. Petros, S. Lilly, P. H. Davis, T. Foster, et al. “Phase I trial of continuously infused gemcitabine with mitoxantrone for high risk or relapsed acute leukemia.” BLOOD 96, no. 11 (November 16, 2000): 326A-326A.

Rizzieri DA, Gockerman JP, DeCastro CM, Petros WP, Lilly S, Davis PH, et al. Phase I trial of continuously infused gemcitabine with mitoxantrone for high risk or relapsed acute leukemia. BLOOD. 2000 Nov 16;96(11):326A-326A.

Rizzieri DA, Gockerman JP, DeCastro CM, Petros WP, Lilly S, Davis PH, Foster T, Jarrell E, Laughlin MJ, Adams DJ, Moore JO. Phase I trial of continuously infused gemcitabine with mitoxantrone for high risk or relapsed acute leukemia. BLOOD. AMER SOC HEMATOLOGY; 2000 Nov 16;96(11):326A-326A.

BLOOD

0006-4971

November 16, 2000

326A / 326A

AMER SOC HEMATOLOGY